<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662099</url>
  </required_header>
  <id_info>
    <org_study_id>CS1+BCMA bispecific CART</org_study_id>
    <nct_id>NCT04662099</nct_id>
  </id_info>
  <brief_title>T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Safety and Efficacy of the Bispecific CAR T Therapy Targeting CS1 and BCMA in Patients With Relapsed/ Refractory Multiple Myeloma: a Single-center, Open-label, Single-arm Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Si'an Medical Technology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of&#xD;
      the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory&#xD;
      multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Multiple myeloma(MM) is one of the most common hematological malignancies with&#xD;
           substantial morbidity and mortality.&#xD;
&#xD;
        -  In recent years, several new therapies have prolonged survival of patients with MM, but&#xD;
           it is still an incurable malignancy of plasma cells.&#xD;
&#xD;
        -  B-cell maturation antigen (BCMA) is expressed by normal and malignant plasma cells and a&#xD;
           small subset of B cells. This specific expression pattern makes BCMA an ideal target&#xD;
           antigen for immunotherapies in MM.&#xD;
&#xD;
        -  BCMA-targeted chimeric antigen receptor (CAR) T cells have exhibited significant&#xD;
           efficacy in MM, but relapse due to single-target escape or poor in vivo persistence has&#xD;
           been reported.&#xD;
&#xD;
        -  Dual-targets or sequential infusion have been proposed to reduce relapse and improve&#xD;
           outcomes post BCMA-specific CAR T therapies.&#xD;
&#xD;
        -  CS1 is expressed on pro-B cells and plasma cells especially malignant ones and some&#xD;
           evidence suggests it plays a role in stromal cell interaction in the BM tumour&#xD;
           microenvironment.&#xD;
&#xD;
        -  We have constructed a bispecific CAR containing anti-CS1 single chain variable region&#xD;
           (scFv) and an anti-BCMA scFv in 4-1BB-containing second-generation formats.&#xD;
&#xD;
        -  The bispecific CAR T cells have exhibited potent cytotoxicity in various BCMA+ or/and&#xD;
           CS1+ MM cells and can effectively eradicate MM cells in xenograft mice models.&#xD;
&#xD;
        -  This study aims to evaluate prelimary safety and efficacy of the CS1&amp;BCMA CAR T cells in&#xD;
           patients with relapsed or refractory MM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related Adverse Events</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate(ORR) and complete response rate(CRR) of administering T cells Expressing a bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>OR and CRR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS), duration of Response(DOR), progress-free survival(PFS) of administering T cells Expressing a bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>OS, PFS and DOR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>In vivo expansion and survival of CS1&amp;BCMA bispecific CAR T cells</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>In vivo (bone marrow and peripheral blood) rate and quantity will be determined by using flow cytometry and qPCR.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>CS1+ or BCMA+ Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Conditioning chemotherapy plus CAR T cells infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conditioning chemotherapy followed by CAR T cell infusion</intervention_name>
    <description>Conditioning chemotherapy: Cyclophosphamide 250 mg/m^2 and fludarabine 30 mg/m^2 IV infusion on days -5, -4, and -3 CAR T cells infusion: 0.75x10^6-6.0X10^6 CAR+ T cells per kg of recipient bodyweight. if DLTs don't occur at the dose of 6.0X10^6 CAR+ T cells per kg, the investigators will discuss whether to try higher dose.</description>
    <arm_group_label>Conditioning chemotherapy plus CAR T cells infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each potential subject must meet all of the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Aged 18-78 years old, males or females.&#xD;
&#xD;
          2. Relapsed or refractory multiple myeloma according to IMWG diagnostic criteria.&#xD;
&#xD;
          3. Received at least 2 prior lines of treatment for multiple myeloma, including a&#xD;
             proteasome inhibitor and an immunomodulatory drug.&#xD;
&#xD;
          4. Detectable MM cells in bone marrow by conventional morphologic methods or flow&#xD;
             cytometry, and positive expression of CS1 or BCMA on MM cells as confirmed by&#xD;
             immunohistochemistry or flow cytometry.&#xD;
&#xD;
          5. Measurable diseases at screening as defined by any of the following:&#xD;
&#xD;
               -  Serum M-protein level ≥1.0g/dL;&#xD;
&#xD;
               -  Urine M-protein level ≥200mg/24 hours;&#xD;
&#xD;
               -  Serum immunoglobulin free light chain(FLC) ≥10 mg/dL provided abnormal FLC ratio.&#xD;
&#xD;
          6. Recovery to grade 1 or baseline of toxicities due to prior treatment, excluding&#xD;
             hematologic toxicities and toxicity of no clinical significance, like alopecia.&#xD;
&#xD;
          7. ECOG Performance Status 0 ~ 2 (ECOG status of larger than 2 points caused by MM&#xD;
             osteolytic destruction is accepted).&#xD;
&#xD;
          8. Good organ function at screening as defined by any of the following:&#xD;
&#xD;
               -  AST and ALT ≤ 2.5×upper limit of normal (ULN);&#xD;
&#xD;
               -  Total bilirubin≤ 2.0×ULN;&#xD;
&#xD;
               -  Creatinine clearance ≥30 mL/min/1.73m2;&#xD;
&#xD;
               -  Ejection fraction of heart ≥50%, and no clinically significant abnormal ECG&#xD;
                  findings.&#xD;
&#xD;
          9. Clinical laboratory values meeting the following criteria at screening:&#xD;
&#xD;
               -  Absolute Neutrophil Count(ANC) ≥1.0×10^9/L;&#xD;
&#xD;
               -  Platelets ≥30×10^9/L;&#xD;
&#xD;
               -  Absolute Lymphocyte Count ≥1.0×10^8/L;&#xD;
&#xD;
               -  Hemoglobin(Hb) ≥6.0g/dL.&#xD;
&#xD;
         10. Women of childbearing potential must have a negative pregnancy test at screening.&#xD;
&#xD;
         11. Patients with extramedullary lesions were eligible.&#xD;
&#xD;
         12. Patients who received prior allogeneic or autologous stem cell transplantation at&#xD;
             least three months before screening were eligible.&#xD;
&#xD;
         13. Sign the informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any potential subject who meets any of the following criteria will be excluded from&#xD;
        participating in the study:&#xD;
&#xD;
          1. Evidence of serious viral, bacterial, or uncontrolled systemic fungal infection.&#xD;
&#xD;
          2. Seropositive for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          3. Seronegative for hepatitis B antigen or a known history of hepatitis B.&#xD;
&#xD;
          4. Hepatitis C (anti-hepatitis C virus [HCV] antibody positive or HCV-RNA quantitation&#xD;
             positive) or a known history of hepatitis C.&#xD;
&#xD;
          5. Systemic corticosteroid therapy of greater than 5 mg/day of prednisone or equivalent&#xD;
             dose within 2 weeks prior to apheresis.&#xD;
&#xD;
          6. Active autoimmune disease or a history of autoimmune disease within 3 years.&#xD;
&#xD;
          7. The following cardiac conditions: Myocardial infarction or coronary artery bypass&#xD;
             graft ≤6 months prior to enrollment; History of clinically significant ventricular&#xD;
             arrhythmia or unexplained; New York Heart Association stage III or IV congestive heart&#xD;
             failure.&#xD;
&#xD;
          8. A history of epilepsy or other central nervous system diseases or altered mental&#xD;
             status.&#xD;
&#xD;
          9. Known life-threatening allergies, hypersensitivity, or intolerance to BM38 CAR T cells&#xD;
             or relevant lymphodepleting regimens (cyclophosphamide and fludarabine).&#xD;
&#xD;
         10. Pregnant or breast-feeding, or planning to become pregnant while enrolled in this&#xD;
             study or within one year after receiving study treatment.&#xD;
&#xD;
         11. Any uncontrolled diseases, other than multiple myeloma, that may lead to abnormal&#xD;
             death.&#xD;
&#xD;
         12. Being participating in other intervention studies.&#xD;
&#xD;
         13. Other cases excluded by the Investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heng Mei, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heng Mei, M.D., Ph.D</last_name>
    <phone>86-13986183871</phone>
    <email>hmei@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chenggong Li</last_name>
    <phone>86-18868112136</phone>
    <email>chenggongli@hust.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <email>hmei@hust.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chenggong Li</last_name>
      <email>chenggongli@hust.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE, Chen YY. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020 May 8;11(1):2283. doi: 10.1038/s41467-020-16160-5.</citation>
    <PMID>32385241</PMID>
  </reference>
  <reference>
    <citation>Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021 Feb;18(2):71-84. doi: 10.1038/s41571-020-0427-6. Epub 2020 Sep 25. Review.</citation>
    <PMID>32978608</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>MEI HENG</investigator_full_name>
    <investigator_title>Proferssor, Cheif Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

